Spero Health (US) acquired CleanSlate Centers (US), effectively doubling its footprint and expanding into new states, according to a public healthcare merger disclosure document. The deal closed on July 1, 2026.

AcquirerSpero Health
TargetCleanSlate Centers
Deal ValueUndisclosed
Type of DealAcquisition
Close Date2026-07-01
Announcement Date2026-07-09
Buy-Side Financial AdvisorsNot disclosed
Sell-Side Financial AdvisorsNot disclosed
Legal Advisors (Buy-side)Not disclosed
Legal Advisors (Sell-side)Not disclosed

The acquisition was aimed at saving CleanSlate Centers from closure due to financial pressures and regulatory challenges. Combined, the companies now operate 128 locations across Arizona, Indiana, Kentucky, Massachusetts, Ohio, Pennsylvania, Tennessee, Virginia, West Virginia, and Wisconsin.

Deal Mechanics

Spero Health assumed CleanSlate Centers' equity interests in exchange for assuming its debt and covering deal expenses. No financial details were disclosed.

Strategic Rationale

The acquisition is seen as a strategic move to strengthen Spero's position in the opioid treatment market, which faces common headwinds such as declining payer reimbursements, rising labor costs, and stricter regulatory environments. The deal aims to leverage economies of scale and enhance operational efficiency.

Financial Context

The addiction treatment sector has seen a slowdown in M&A activity due to increased regulatory scrutiny, reduced investor appetite for high-risk deals, and challenges related to payer reimbursement policies. Spero Health’s acquisition reflects its focus on consolidating the market amid these pressures.

Advisors

The details of financial and legal advisors for both parties remain undisclosed.

Outlook

Spero Health aims to integrate CleanSlate Centers’ operations seamlessly, maintaining existing services as is. The company plans to expand its service offerings in the future to address market demands and regulatory requirements effectively.